BioCentury
ARTICLE | Company News

Complete Genomics, Illumina genomics news

October 29, 2012 7:00 AM UTC

The U.S. District Court for the Northern District of California granted a partial summary judgment to Complete Genomics invalidating a number of claims in Illumina's U.S. Patent No. 6,306,597 covering DNA sequencing by parallel oligonucleotide extensions. The court said the claims are invalid due to prior art. Complete Genomics said it "strongly believes" that it did not infringe the remaining claims of the '597 patent and said it "intends to continue to vigorously defend itself." Illumina said it does not comment on pending legal matters.

Illumina filed suit in August 2010 in the District Court for the District of Delaware alleging that Complete Genomics' Complete Genomics Analysis (CGA) technology infringes the '597 patent and Illumina's U.S. Patent Nos.7,232,656 and 7,598,035. In November 2010, the Delaware court transferred the case to the Northern District of California. At the time, Complete Genomics and Illumina agreed to dismiss without prejudice all of the claims and counterclaims related to the '656 and '035 patents. The '656 patent covers arrayed biomolecules and their use in sequencing, and the '035 patent covers method and compositions for ordering restriction fragments (see BioCentury, Aug. 23, 2010 & May 23, 2011). ...